Combined Corticosteroid Injections and Shockwave Therapy for Sacroiliac Joint Pain

Tri-Service General Hospital

Status: Begins enrollment in 2 months

Conditions: Sacroiliac Joint Pain; Sacroiliac Joint Dysfunction

Treatments: Device: extracorporeal shockwave(minimum intensity); Drug: Corticosteroids Triamcinolone Acetonide; Device: extracorporeal shockwave

Study type: Interventional

Funder types: Other

Identifiers

NCT06761768

B202405209

Details and patient eligibility

About

This study aims to investigate the combined use of corticosteroid injections and ESWT for SIJ pain.

Full description

The most common primary cause of pain and stiffness from the SIJ is sacroiliac joint dysfunction. Currently, conservative treatments for SIJ dysfunction-related pain include oral anti-inflammatory pain medications, exercise therapy, physical therapy, and local injection therapies such as corticosteroids, dextrose, and platelet-rich plasma. Although there are multiple non-surgical options available for SIJ pain management, clear treatment guidelines have not yet been established. Among these options, intra-articular corticosteroid injections in the SIJ are frequently used by rehabilitation specialists in clinical practice, and their effectiveness in relieving pain from SIJ dysfunction has been demonstrated. However, the effects of corticosteroids in treating musculoskeletal-related diseases are typically short-term. Extracorporeal shock wave therapy (ESWT) has become increasingly common in the management of musculoskeletal conditions such as calcific tendinitis, tennis elbow, and plantar fasciitis, showing long-lasting benefits and inducing tissue repair responses that studies suggest may last up to two years. However, literature on ESWT for lower back pain is limited, and research on its use for SIJ pain is even rarer. Therefore, this study aims to investigate the combined use of corticosteroid injections and ESWT for SIJ pain, aiming to achieve rapid, short-term pain relief through corticosteroid injections, followed by potential long-term effects through ESWT.

Enrollment: 44 estimated patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Low back pain lasting for 3 months or more
• Pain VAS score of 4 or higher
• Three or more positive results in sacroiliac joint provocation tests
• At least 50% pain relief following ultrasound-guided sacroiliac joint injection with local anesthetic

Exclusion criteria

• Currently undergoing extracorporeal shockwave therapy in other areas
• Suspected pain caused by other lumbar spine or hip joint conditions (e.g., lumbar spine or disc disorders, radicular pain, spondylolisthesis/disc degeneration, hip arthritis)
• Presence of complex comorbidities, including trauma, systemic infections (e.g., fever, chills, night sweats), local sacroiliac joint infections, autoimmune diseases, or immunosuppression
• Sacroiliac joint injection therapy received within the past 6 months
• Contraindications for extracorporeal shockwave therapy (e.g., cancer or current/prior infections at the treatment site, pacemakers, pregnancy, epilepsy, or coagulation disorders caused by disease or medication)
• Impaired renal function preventing the administration of contrast agents for sacroiliac joint bone scanning

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

44 participants in 2 patient groups

Corticosteroid Injection and shockwave Therapy

Experimental group

Description:

Participants received ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine). One week later, they began a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session).

Treatment:

Device: extracorporeal shockwave

Drug: Corticosteroids Triamcinolone Acetonide

Corticosteroid Injection and sham shockwave Therapy

Sham Comparator group

Description:

Participants received ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine). One week later, they began a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session).

Treatment:

Drug: Corticosteroids Triamcinolone Acetonide

Device: extracorporeal shockwave(minimum intensity)